Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of 300 mg vs 150 mg erlotinib in current smokers with advanced NSCLC after chemotherapy failure
2010-018476-24Phase 3Completed
- Sponsor
- Roche
- Start
- May 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of erlotinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Roche. Primary endpoint: Progression-free survival. Started May 2010; status: completed.
02
Drugs
erlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2010-018476-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-018476-24.